Centiva Capital LP purchased a new position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,244 shares of the company's stock, valued at approximately $355,000.
Several other institutional investors have also made changes to their positions in the stock. Principal Financial Group Inc. acquired a new position in Astrana Health in the third quarter worth approximately $13,383,000. Franklin Resources Inc. bought a new position in shares of Astrana Health during the 3rd quarter valued at $1,187,000. Barclays PLC acquired a new stake in shares of Astrana Health in the 3rd quarter valued at $4,457,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Astrana Health by 348.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,788 shares of the company's stock worth $1,191,000 after purchasing an additional 29,355 shares in the last quarter. Finally, Truist Financial Corp acquired a new position in Astrana Health during the fourth quarter worth $315,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have weighed in on ASTH shares. Robert W. Baird reduced their price target on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Barclays began coverage on shares of Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price objective for the company. Stifel Nicolaus cut their price target on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Truist Financial dropped their price objective on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Finally, Bank of America reduced their target price on Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $53.29.
View Our Latest Research Report on ASTH
Astrana Health Trading Up 2.1%
Shares of NASDAQ ASTH traded up $0.56 during midday trading on Thursday, hitting $27.06. The stock had a trading volume of 339,277 shares, compared to its average volume of 286,870. The firm has a market cap of $1.52 billion, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 1.37 and a beta of 1.00. Astrana Health, Inc. has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The company's 50-day simple moving average is $30.86 and its 200 day simple moving average is $35.82.
Astrana Health (NASDAQ:ASTH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $620.39 million for the quarter, compared to analyst estimates of $628.11 million. During the same quarter in the previous year, the company posted $0.31 earnings per share. The business's revenue for the quarter was up 53.4% on a year-over-year basis. Research analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Company Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Read More
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
